{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004192","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.865086+00:00","generated_at":"2026-06-20T17:53:16.464465+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Stoke updates STK-001 Dravet data timelines: 45mg mid-2023, 70mg H2 2023; STK-002 ADOA Phase 1/2 start 2024","bullets":["Multiple-dose STK-001 45mg data expected mid-2023; 70mg data expected second half 2023.","Phase 1/2a for Dravet syndrome to complete in 2023, enabling Phase 3 program in 2024.","STK-002 for ADOA: UK CTA submission expected H1 2023; Phase 1/2 start planned for 2024.","Updated corporate presentation posted ahead of J.P. Morgan Healthcare Conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004192","json":"https://secwatch.observer/filing/0001193125-23-004192.json","markdown":"https://secwatch.observer/filing/0001193125-23-004192.md","text":"https://secwatch.observer/filing/0001193125-23-004192.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000119312523004192/0001193125-23-004192-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000119312523004192/d427248d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:53:16.464465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}